Latest News and Press Releases

BOTHELL, Wash., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that President and co-interim CEO Sam Lee, PhD will present a company overview of their antiviral...

BOTHELL, Wash., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that President and co-interim CEO Sam Lee, PhD will present data from the Company’s Phase 1...

BOTHELL, Wash., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces the selection of its novel, broad-spectrum antiviral drug candidate CDI-988 for clinical development...

BOTHELL, Wash., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that James Martin, CFO and interim co-CEO, will present a company overview at the Dawson James...

BOTHELL, Wash., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces that its Board of Directors has approved a 1-for-12 reverse stock split...

BOTHELL, Wash., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that management will participate virtually in the hybrid in-person and virtual H.C. Wainwright 24th...

Planned Phase 2a study design with orally administered CC-42344 for the treatment of pandemic and seasonal influenza AReported pharmacokinetic (PK) data from the single ascending dose portion of its...

BOTHELL, Wash., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces it has engaged hVIVO, a subsidiary of London-based Open Orphan plc...

Single Ascending Dose Portion of Phase 1 Study Completed BOTHELL, Wash., July 14, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that...

BOTHELL, Wash., June 01, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces a Non-Clinical Evaluation Agreement (NCEA) with the National...